

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



June 25, 2021

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

NSE Code: SUNPHARMA

BSE Code: 524715

Dear Sir / Madam,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the details of related party transactions on consolidated basis for the half year ended March 31, 2021 in the format specified in the relevant accounting standards for annual results.

This is for your information and record.

Thanking you,

Yours faithfully,
For **Sun Pharmaceutical Industries Limited**

Ashok I. Bhuta
Compliance Officer

Encl: As above

SUN PHARMACEUTICAL INDUSTRIES LIMITED

Related Party disclosure on a consolidated basis - Half year ended March 31, 2021

Names of related parties where there are transactions and description of relationships**a Key Management Personnel (KMP)**

Dilip Shantilal Shanghvi

Managing Director (DIN:
00005588)

Israel Makov

Chairman and Non- Executive
Director (Non- Independent)
(DIN : 05299764)

Kalyanasundaram Iyer Natesan Subramanian

Wholetime Director (DIN :
00179072)

Sailesh Trambaklal Desai

Wholetime Director (DIN:
00005443)

Sudhir Vrundavandas Valia

Non-Executive and Non-
Independent Director
(DIN : 00005561)**b Relatives of Key Management Personnel**

Aalok Shanghvi

Vidhi Shanghvi

c Others (Entities in which the KMP and Relatives of KMP have control or significant influence)

Alfa Infraprop Private Limited

Kism Textiles Private Limited

Makov Associates Limited

PV Power Technologies Private Limited

Shanghvi Finance Private Limited

Sidmak Laboratories (India) Private Limited

Sun Petrochemicals Private Limited

Sun Pharma Advanced Research Company Limited

Shantilal Shanghvi Foundation

United Medisales Private Limited

d Joint Venture

Artes Biotechnology GmbH

e Associates

Dy Py Institute LLC

Intact Solution LLC

Medinstill Development LLC

f Unconsolidated Subsidiary

Foundation for Disease Elimination and Control of India

SUN PHARMACEUTICAL INDUSTRIES LIMITED

Transactions during half year ended March 31, 2021 with related parties :	₹ In Million
	Half Year ended March 31, 2021
Purchase of goods	209.4
Others	209.4
Purchase of property, plant and equipment and other intangible assets	46.2
Others	46.2
Revenue from contracts with customers, net of returns	107.2
Others	107.2
Sale of property, plant and equipment and other intangible assets	11.7
Others	11.7
Other operating revenue /Other income	22.7
Others	22.7
Receiving of service	742.7
Joint venture	6.5
Others	736.2
Reimbursement of expenses (Paid)	75.6
Associate	3.3
Others	72.3
Rendering of service	138.4
Others	138.4
Reimbursement of expenses (Received)	24.5
Others	7.1
Unconsolidated subsidiary (March 31, 2021 : ₹ 4,793)	0.0
Key management personnel	17.4
Investment in Associate	56.4
Associate	56.4
Lease Rental and hire charges (Income)	11.3
Others	11.3
Rent expense / Payment towards Lease Liabilities	4.8
Others	4.8
Remuneration/ compensation	132.2
Key management personnel	113.7
Relatives of Key management personnel	18.5
Donation	214.5
Others	200.0
Unconsolidated subsidiary	14.5

NOTE :

1 Drawn in accordance with applicable accounting standards for the period Half year ended March 2021.

2 Key management Personnel (KMP) and Relatives of KMP who are under the employment of the Company are entitled to post employment benefits and other long term employee benefits recognised as per Ind AS 19 - 'Employee Benefits'. As these employee benefits are lump sum amount provided on the basis of actuarial valuation, the same is not included above and there is no Share-based payments to key management personnel and relatives of KMP.